Phase 1b Study of a Cancer Vaccine to Treat Patients With Advanced Stage Ovarian, Fallopian or Peritoneal Cancer

NCT03332576 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

37

Enrollment

INDUSTRY

Sponsor class

Conditions

Epithelial Ovarian Cancer
Fallopian Tube Cancer
Peritoneal Cancer

Interventions

BIOLOGICAL: DPX-Survivac
BIOLOGICAL: DPX-Survivac(Aqueous)
DRUG: Cyclophosphamide

Sponsor

ImmunoVaccine Technologies, Inc. (IMV Inc.)